231 related articles for article (PubMed ID: 36510904)
1. Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises.
Soren UK; Mohanty PK; Meher S; Sukla SK; Hiregoudar M
Indian J Med Res; 2022 Jul; 156(1):122-129. PubMed ID: 36510904
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
Ballas SK; Bauserman RL; McCarthy WF; Castro OL; Smith WR; Waclawiw MA;
J Pain Symptom Manage; 2010 Dec; 40(6):870-82. PubMed ID: 20864308
[TBL] [Abstract][Full Text] [Related]
3. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
[TBL] [Abstract][Full Text] [Related]
5. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
[TBL] [Abstract][Full Text] [Related]
6. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
Azmet FR; Al-Kasim F; Alashram WM; Siddique K
Saudi Med J; 2020 Jan; 41(1):46-52. PubMed ID: 31915794
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
8. A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain.
de Franceschi L; Finco G; Vassanelli A; Zaia B; Ischia S; Corrocher R
Haematologica; 2004 Nov; 89(11):1389-91. PubMed ID: 15531461
[TBL] [Abstract][Full Text] [Related]
9. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
10. Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department.
García-Morin M; López-Sangüos C; Vázquez P; Alvárez T; Marañón R; Huerta J; Cela E
Hemoglobin; 2016 Nov; 40(6):388-391. PubMed ID: 28361592
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
12. [Sickle cell anemia in children: value of hydroxyurea in severe forms].
Oury AP; Hoyoux C; Dresse MF; Chantraine JM
Arch Pediatr; 1997 Sep; 4(9):839-44. PubMed ID: 9345564
[TBL] [Abstract][Full Text] [Related]
13. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
14. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
[TBL] [Abstract][Full Text] [Related]
15. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421
[TBL] [Abstract][Full Text] [Related]
16. Arterialization of venous blood for differentiation of sickle cell subjects in vaso-occlusive crisis.
Nahavandi M; Tavakkoli F; Wyche MQ; Perlin E; Millis RM
Hematology; 2003 Dec; 8(6):421-8. PubMed ID: 14668039
[TBL] [Abstract][Full Text] [Related]
17. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
18. A systematic review on hydroxyurea therapy for sickle cell disease in India.
Pandey A; Kaur H; Borah S; Khargekar N; Karra VK; Adhikari T; Jain D; Madkaikar M
Indian J Med Res; 2022 Aug; 156(2):299-311. PubMed ID: 36629190
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease.
Pinto VM; Gianesin B; Sardo S; Mazzi F; Baiardi G; Menotti S; Piras F; Quintino S; Robello G; Mattioli F; Finco G; Forni GL; De Franceschi L
Orphanet J Rare Dis; 2024 Jan; 19(1):22. PubMed ID: 38254184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
